Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.72 |
| ▸ | JAK3 | P52333 | 6/20 | 0.72 |
| ▸ | BTK | Q06187 | 6/20 | 0.72 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.72 |
| ▸ | KIT | P10721 | 2/20 | 0.72 |
| ▸ | SRC | P12931 | 2/20 | 0.72 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.72 |
| ▸ | ITK | Q08881 | 2/20 | 0.72 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.72 |
| ▸ | CIT | O14578 | 1/20 | 0.72 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.72 |
| ▸ | GAK | O14976 | 1/20 | 0.72 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.72 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.72 |
| ▸ | STK17B | O94768 | 1/20 | 0.72 |
| ▸ | STK10 | O94804 | 1/20 | 0.72 |
| ▸ | ABL1 | P00519 | 1/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14040940 | 0.84 | EGFR (0.81) | EGFRERBB2JAK3BTKERBB4 | |
| Canertinib SCHEMBL29623482 | 0.84 | EGFR (1.00) | EGFRERBB2JAK3BTKERBB4 | |
| Canertinib SCHEMBL54837 | 0.84 | EGFR (1.00) | EGFRERBB2JAK3BTKERBB4 | |
| Canertinib SCHEMBL29655741 | 0.84 | EGFR (1.00) | EGFRERBB2JAK3BTKERBB4 | |
| Canertinib SCHEMBL29368458 | 0.84 | EGFR (1.00) | EGFRERBB2JAK3BTKERBB4 | |
| Canertinib SCHEMBL30436576 | 0.83 | EGFR (1.00) | EGFRERBB2JAK3BTKERBB4 | |
| Canertinib SCHEMBL2141065 | 0.83 | EGFR (1.00) | EGFRERBB2JAK3BTKERBB4 | |
| Canertinib SCHEMBL2052123 | 0.83 | EGFR (1.00) | EGFRERBB2JAK3BTKERBB4 | |
| SCHEMBL7622647 | 0.83 | EGFR (0.57) | EGFRERBB2JAK3BTKERBB4 | |
| Canertinib SCHEMBL731396 | 0.83 | EGFR (0.97) | EGFRERBB2JAK3BTKERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723341-B2 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-05-25 | — | — | US | disclosed |
| US-20090186875-A1 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186875-A1 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | DPYD, DHODH, FH | EGFR 2434/4885ERBB2 2892/4885JAK3 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.